Better Care for PFAS Patients Act of 2026

This bill requires the Director of the Agency for Toxic Substances and Disease Registry to make an agreement within 60 days with the National Academies of Sciences, Engineering, and Medicine (or another entity) to study the health effects of PFAS chemicals that can be measured in human tissues and to write clinical recommendations for addressing those effects. The first study and recommendations are due within 2 years of the agreement and must be updated every 5 years or more often if needed. The study must include input from communities exposed to PFAS. Within 5 years of the agreement, and every 5 years after, the agency must issue clinical guidance, post it on its website, and share it with state and local health authorities and health care professionals.

Full text and official record on Congress.gov

Sponsors

• Jeanne Shaheen Democrat sponsor
• 1 cosponsors